Compare
Vera Therapeutics, Inc. vs Schrodinger, Inc. vs Aurinia Pharmaceuticals Inc. vs Arvinas, Inc.
| Latest fiscal year | Vera Therapeutics, Inc. VERA | Schrodinger, Inc. SDGR | Aurinia Pharmaceuticals Inc. AUPHRevenue covers only part of its income (partial revenue) | Arvinas, Inc. ARVN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $255.87M | n/a | $262.60M |
| Revenue growth (YoY) | n/a | +23.3% | n/a | -0.3% |
| Gross margin | n/a | 55.7% | n/a | n/a |
| Operating margin | n/a | -65.2% | n/a | -45.1% |
| Net margin | n/a | -40.4% | n/a | -30.8% |
| Net income | -$299.62M | -$103.27M | $287.20M | -$80.80M |
| EPS (Diluted) | -$4.66 | -$1.41 | $2.07 | -$1.14 |
| Operating cash flow | -$241.10M | $13.90M | $135.66M | -$273.80M |
| Free cash flow | -$241.73M | $12.46M | n/a | -$275.70M |
| Cash & equivalents | $354.73M | $230.52M | $80.16M | $142.90M |
| Total assets | $734.73M | $726.16M | $751.59M | $717.90M |
| Total liabilities | $130.21M | $362.11M | $170.26M | $284.00M |
| Shareholders' equity | $604.52M | $364.05M | $581.33M | $433.90M |
| Return on year-end equity | -49.6% | -28.4% | 49.4% | -18.6% |
| Shares outstanding | n/a | n/a | 132.32M | 63.50M |
Revenue, most recent five fiscal years
| Fiscal year | Vera Therapeutics, Inc. | Schrodinger, Inc. | Aurinia Pharmaceuticals Inc. | Arvinas, Inc. |
|---|---|---|---|---|
| Latest | n/a | $255.87M Ended 2025-12-31 | n/a | $262.60M Ended 2025-12-31 |
| 1 year earlier | n/a | $207.54M Ended 2024-12-31 | n/a | $263.40M Ended 2024-12-31 |
| 2 years earlier | n/a | $216.67M Ended 2023-12-31 | n/a | $78.50M Ended 2023-12-31 |
| 3 years earlier | n/a | $180.96M Ended 2022-12-31 | n/a | $131.40M Ended 2022-12-31 |
| 4 years earlier | n/a | $137.93M Ended 2021-12-31 | n/a | $53.60M Ended 2021-12-31 |